Skip to main content
user-generated· event

Yosemite-backed Azalea reaches Phase 3 clinical trials by 2027-06-30

Azalea, a portfolio company of Yosemite Ventures born from Jennifer Doudna's lab, is developing a novel cancer therapy. With Yosemite's rapid advancements in oncology drug discovery and AI integration, Azalea is poised to advance to Phase 3 trials within 12 months, aligning with industry benchmarks for similar oncology programs.

event · Prediction Market

Implied probability (Yes)
65%
Closes
2027-06-30

More event markets

Browse all event markets →

Loading…